iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

What the release reports

iBio described results from an eight-week obese non-human primate (NHP) study (n=6 per group) that evaluated IBIO-610, an Activin E antibody candidate, administered alone and in combination with semaglutide, a GLP-1 receptor agonist. The company reported that when IBIO-610 was combined with semaglutide, a smaller portion of the observed weight loss was lean mass compared with semaglutide alone. The press release also highlights pharmacodynamic and pharmacokinetic measures, and states an intention to begin first-in-human studies in the first half of 2027.

Sources: S1

Key study findings reported

iBio reported that in the eight-week NHP study, lean mass made up 6% of weight lost with IBIO-610 plus semaglutide versus 22% with semaglutide alone, and in a related analysis at week 8, fat accounted for 93% of weight lost with IBIO-610 plus twice-weekly semaglutide versus 77% with semaglutide alone. The company also reported a 97% reduction in serum levels of active Activin E at week 8 following a single intravenous dose of IBIO-610, and that the molecule had a 33.2-day half-life in NHPs with a projected human half-life that the company says could support twice-yearly dosing.

Sources: S1

Company plans and context

iBio characterizes IBIO-610 as a potential first-in-class Activin E antibody and said the data were discussed in an oral presentation at the European Association for the Study of Diabetes Annual Meeting on October 1, 2026. The company stated it expects to start first-in-human trials of IBIO-610 in the first half of 2027.

Sources: S1

Why this may matter (inference)

If the reported findings translate to humans, a therapy that shifts the composition of weight loss toward fat and preserves lean mass when combined with GLP-1 therapy could address clinical interest in weight-loss quality. The company’s biomarker reduction and reported half-life are relevant to dosing and target engagement assumptions that iBio cites in describing next steps toward clinical testing.

Sources: S1

What remains uncertain

• All quantitative results and projections are reported by iBio from a preclinical non-human primate study and have not been independently verified.
• The press release contains forward-looking statements, including that iBio expects to start first-in-human trials of IBIO-610 in the first half of 2027 and that a projected human half-life could potentially support twice-yearly dosing; these are subject to development and regulatory risks.
• Findings in non-human primates may not be replicated in humans and the release does not report statistical measures of uncertainty, responder variability, or safety data sufficient to establish human tolerability.